Neptunus To 'Save' Subsidiary Interlong Biotech With RMB 443 Million Transfer
This article was originally published in PharmAsia News
Executive Summary
Neptunus Biotech recently issued a notice outlining plans to transfer its entire 80 percent stake in Neptunus Fuyao Pharmaceutical to its ailing subsidiary Neptunus Interlong